Philadelphia just scored a heavyweight win in the life sciences arena, with Alveus Therapeutics boosting its Series A haul to $197 million and officially shifting its U.S. headquarters to Center City. The obesity and metabolic disease startup says the fresh cash will fuel clinical work and expand its drug pipeline, while the move plants a new flag in Philly’s growing biotech corridor.
Led by CEO Raj Kannan, Alveus is splitting its footprint across two continents, keeping research operations in Copenhagen while building out U.S. operations in Philadelphia. The extended Series A brings in a mix of specialist healthcare funds and strategic pharma investors that the company says it plans to lean on as it ramps up development.
Second Close Pushes Round To $197 Million
The funding total hit $197 million with a second and final closing of an oversubscribed Series A, which brought in Jeito Capital as a cornerstone investor alongside Novo Holdings and other healthcare funds, according to a company release. The proceeds are earmarked for clinical development of ALV‑100 and to move several amylin‑based candidates toward IND filings.
The initial chunk of the Series A launched in January at roughly $160 million. The extension did not just pad the total, it widened the investor roster to include New Rhein Healthcare Investors, Andera Partners and Omega Funds, as outlined in a press release via BioSpace.
Alveus Plants Its Flag In Center City
Alveus says it has officially moved its headquarters to Philadelphia and is expanding its U.S. presence from shared office space in the downtown Two Logan Square building. Between the relocation and the size of the financing, this counts as one of the biggest life‑sciences rounds in the region so far this year, as reported by the Philadelphia Business Journal.
The company was incubated and funded by New Rhein Healthcare Investors, but leadership now plans to run U.S. operations from Philadelphia while keeping R&D concentrated in Copenhagen. For Philly, that means another biotech name on the building directory and the prospect of more lab and office jobs over time.
Pipeline And Clinical Milestones
Alveus’ lead asset, ALV‑100, is a bifunctional GIP receptor antagonist and GLP‑1 receptor agonist designed to deliver durable weight loss with better tolerability than existing options. In a press release via Alveus Therapeutics, the company said the FDA has cleared an IND and the first patient was dosed in a Phase 1b obesity study in January.
Company materials and investor communications say that the new funding will support later‑stage development of ALV‑100 and bankroll IND filings for amylin‑based programs that are next in the queue.
Local Ecosystem And Hiring
Philadelphia’s life‑sciences ecosystem has been steadily stacking wins, and Alveus’ decision to set up its U.S. base here fits that trend. The Philadelphia Inquirer reported that Alveus has roughly 50 employees split between Copenhagen and Philadelphia, with U.S. staff currently operating from shared space downtown.
Local investors and incubators say that rounds of this size help solidify Philadelphia’s status as an operating hub rather than a mere satellite outpost for coastal biotech firms, and Alveus now becomes one of the higher profile test cases for that thesis.
Next Milestones On The Road Ahead
Company leaders and investors say this cash gives Alveus enough runway to hit key clinical “make or break” moments over the next couple of years. That includes pushing ALV‑100 toward Phase 2 readiness and launching first‑in‑human studies for other candidates in the pipeline over the next 18 to 24 months.
“The backing of specialist healthcare investors with deep domain expertise reflects strong momentum for Alveus,” the company said in a statement that went out with the financing announcement via GlobeNewswire.
Observers caution that the real judgment will come with clinical readouts and hiring numbers, and whether Alveus can convert this war chest into sustainable operations and long‑term jobs on both sides of the Atlantic.
